Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
November 18, 2024 08:00 ET
|
Allarity Therapeutics, Inc.
Two patients exceed 14 months on treatment in Phase 2 trial of advanced ovarian cancerAllarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate stenoparib’s clinical...
Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights
November 14, 2024 08:00 ET
|
Allarity Therapeutics, Inc.
Cash balance at $18.5 millionStrengthened leadership team with new members driving stenoparib developmentNASDAQ compliance regained Boston (November 14, 2024)—Allarity Therapeutics, Inc....
Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib
October 22, 2024 08:00 ET
|
Allarity Therapeutics, Inc.
European Patent Office to grant a patent for DRP® companion diagnostic for Allarity’s stenoparib cancer therapy Patent applications for the Stenoparib DRP® are also pending in the US, Japan, China,...
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
October 10, 2024 08:00 ET
|
Allarity Therapeutics, Inc.
Boston (October 10, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments,...
Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program
October 03, 2024 08:00 ET
|
Allarity Therapeutics, Inc.
Former Eli Lilly Research Fellow Jeremy R. Graff, Ph.D., appointed as President and Chief Development Officer to lead the Company’s clinical development programsEli Lilly and Celgene veteran Jose...
Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial
September 16, 2024 08:00 ET
|
Allarity Therapeutics, Inc.
- Durable Clinical Benefit Observed Beyond a Year on Treatment in Heavily Pre-Treated Patients Boston (September 16, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR),...
Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 13, 2024 08:45 ET
|
Allarity Therapeutics, Inc.
- New CFO Brings Multiple Years of Experience from Biotech Companies- As Part of the New Hire, the Company Issues Inducement Grants Boston (September 13, 2024) — Allarity Therapeutics, Inc....
Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)
September 11, 2024 08:00 ET
|
Allarity Therapeutics, Inc.
Boston (September 11, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments,...
Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting
July 26, 2024 09:00 ET
|
Allarity Therapeutics, Inc.
Boston (July 26, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer...
Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares
July 24, 2024 06:00 ET
|
Allarity Therapeutics, Inc.
Boston (July 24, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments,...